Skip to content
Select your cancer type
▼
  • ESCC
  • GC/GEJC
  • NSCLC
Indication:
▼
  • 1 L ESCC
  • 1 L GC/GEJC
  • 2 L ESCC
  • Non-Squamous NSCLC
  • Squamous NSCLC

Language

This site is inteded for health care proffesional.

Spread Hope
with etapidi

A treatment that is designed to work with your immune system and help you live longer

Share with Us Your Condition​

Esophageal Squamous Cell Carcinoma (ESCC)

Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

Non-Small Cell Lung Cancer
(NSCLC)

Clinical Study Results

In a clinical study, people who received ETAPIDI + chemotherapy and whose tumor tested positive for the biomarker PD-L1 lived longer than those who received placebo + chemotherapy

ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; GEJC, gastroesophageal junction cancer; NSCLC, squamous & non squamous non-small cell lung cancer; PD-L1, programmed death ligand 1.